Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 6
2007 13
2008 20
2009 24
2010 44
2011 118
2012 208
2013 286
2014 331
2015 249
2016 111
2017 55
2018 23
2019 14
2020 12
2021 23
2022 14
2023 6
2024 3
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,368 results

Results by year

Filters applied: . Clear all
Page 1
Telaprevir-related dermatitis.
Roujeau JC, Mockenhaupt M, Tahan SR, Henshaw J, Martin EC, Harding M, van Baelen B, Bengtsson L, Singhal P, Kauffman RS, Stern RS. Roujeau JC, et al. JAMA Dermatol. 2013 Feb;149(2):152-8. doi: 10.1001/jamadermatol.2013.938. JAMA Dermatol. 2013. PMID: 23560295 Clinical Trial.
OBJECTIVE: To evaluate the incidence, type, and severity of telaprevir-associated skin reactions. DESIGN: Three dermatologists assessed available information including photographs, biopsy results, and clinical summaries of all cases with skin eruptions reported as moderate …
OBJECTIVE: To evaluate the incidence, type, and severity of telaprevir-associated skin reactions. DESIGN: Three dermatologists assess …
Telaprevir.
[No authors listed] [No authors listed] Drugs R D. 2010;10(3):179-202. doi: 10.2165/11586020-000000000-00000. Drugs R D. 2010. PMID: 20945948 Free PMC article. Review.
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. ...As the first ever HCV protease inhibitor in phase III development, it is being studied in trial …
Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the …
Telaprevir-induced DRESS.
Kesar V, Kesar V, Khaitova V, Motamed D, Schiano T. Kesar V, et al. J Drugs Dermatol. 2014 Feb;13(2):199-200. J Drugs Dermatol. 2014. PMID: 24509972
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash …
Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCT …
Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.
Fontaine H, Pol S. Fontaine H, et al. Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S59-63. doi: 10.1016/S2210-7401(11)70009-2. Clin Res Hepatol Gastroenterol. 2011. PMID: 22248696 Review.
The triple association of direct-acting antivirals specific of HCV, and especially the first-generation protease inhibitors boceprevir and telaprevir, increases this percentage to around 65%, with variations according to the previous response to therapy of patients …
The triple association of direct-acting antivirals specific of HCV, and especially the first-generation protease inhibitors boceprevi …
Telaprevir.
[No authors listed] [No authors listed] Prescrire Int. 2012 Apr;21(126):93-6. Prescrire Int. 2012. PMID: 22515133
Severe rash occurred in 0.4% of patients receiving telaprevir, and severe anaemia in 4.9%. Telaprevir is metabolised by and inhibits cytochrome P450 isoenzyme CYP 3A4. Telaprevir is also a P-glycoprotein substrate, resulting in a high risk of pharmacokinetic …
Severe rash occurred in 0.4% of patients receiving telaprevir, and severe anaemia in 4.9%. Telaprevir is metabolised by and in …
The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor alpha (ERalpha)-positive breast cancer cells.
Bartoloni S, Leone S, Pescatori S, Cipolletti M, Acconcia F. Bartoloni S, et al. Mol Oncol. 2022 Oct;16(19):3568-3584. doi: 10.1002/1878-0261.13303. Epub 2022 Sep 3. Mol Oncol. 2022. PMID: 36056637 Free PMC article.
The effect of Tel is transduced by the IGF1-R/AKT/FOXA1 pathway, with the antiviral compound interacting with IGF1-R. Tel prevents the proliferation of several BC cell lines, while it does not affect the proliferation of normal nontransformed cell lines, and its antiprolif …
The effect of Tel is transduced by the IGF1-R/AKT/FOXA1 pathway, with the antiviral compound interacting with IGF1-R. Tel prevents th …
[Telaprevir resistance].
Poveda E, García F. Poveda E, et al. Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:26-32. doi: 10.1016/S0213-005X(13)70121-6. Enferm Infecc Microbiol Clin. 2013. PMID: 24063900 Review. Spanish.
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against the hepatitis C virus (HCV), this potency can be compromised by the rapid emergence of resistance mutations. ...The presence of polymorphism …
Telaprevir is an extremely potent antiviral drug. However, as with other direct-acting antiviral agents against …
[Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
Nikitin IG, Gogova LM, Baikova IE, Kislyakov VA, Volynkina VM. Nikitin IG, et al. Ter Arkh. 2012;84(11):75-80. Ter Arkh. 2012. PMID: 23252254 Review. Russian.
The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). ...The paper also provides data on the resistance of telaprevir and i …
The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral …
Telaprevir user's guide.
Liapakis AM, Jacobson I. Liapakis AM, et al. Liver Int. 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. Liver Int. 2012. PMID: 22212567 Review.
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a regimen of telaprevir combined with pegylated interferon alfa and ribavirin (PR) over PR alone in patients with HCV genotype 1. ...Stopp …
Telaprevir is a potent HCV NS3/4A protease inhibitor. A completed development program has demonstrated the superior efficacy of a reg …
Validating Enterovirus D68-2A(pro) as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A(pro) Inhibitor.
Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, Wang J. Musharrafieh R, et al. J Virol. 2019 Mar 21;93(7):e02221-18. doi: 10.1128/JVI.02221-18. Print 2019 Apr 1. J Virol. 2019. PMID: 30674624 Free PMC article.
To further confirm the antiviral drug target, serial viral passage experiments were performed to select for resistance against telaprevir. ...The binding of telaprevir potently inhibits its enzymatic activity, and using drug resistance selection, we show that …
To further confirm the antiviral drug target, serial viral passage experiments were performed to select for resistance against tel …
1,368 results